Multilayer factors associated with excess all-cause mortality during the omicron and non-omicron waves of the COVID-19 pandemic: time series analysis in 29 countries.

Publication date: Feb 02, 2024

The COVID-19 pandemic has resulted in significant excess mortality globally. However, the differences in excess mortality between the Omicron and non-Omicron waves, as well as the contribution of local epidemiological characteristics, population immunity, and social factors to excess mortality, remain poorly understood. This study aims to solve the above problems. Weekly all-cause death data and covariates from 29 countries for the period 2015-2022 were collected and used. The Bayesian Structured Time Series Model predicted expected weekly deaths, stratified by gender and age groups for the period 2020-2022. The quantile-based g-computation approach accounted for the effects of factors on the excess all-cause mortality rate. Sensitivity analyses were conducted using alternative Omicron proportion thresholds. From the first week of 2021 to the 30th week of 2022, the estimated cumulative number of excess deaths due to COVID-19 globally was nearly 1. 39 million. The estimated weekly excess all-cause mortality rate in the 29 countries was approximately 2. 17 per 100,000 (95% CI: 1. 47 to 2. 86). Weekly all-cause excess mortality rates were significantly higher in both male and female groups and all age groups during the non-Omicron wave, except for those younger than 15 years (P 

Open Access PDF

Concepts Keywords
39million COVID-19
Covid Excess all-cause mortality
Pandemic Influencing factors
Younger The Omicron wave

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease VO time
disease VO population
disease MESH death
pathway REACTOME Reproduction
disease VO vaccinated
disease VO organization
disease VO vaccination
disease VO USA
disease VO biweekly
disease VO vaccine
disease VO effective
disease MESH chronic diseases
disease IDO algorithm
drug DRUGBANK Vildagliptin
disease VO Optaflu
disease IDO country
drug DRUGBANK Coenzyme M
disease MESH aids
disease VO efficiency
drug DRUGBANK Aspartame
disease IDO replication
disease VO age
disease MESH bronchiolitis
disease MESH infection
drug DRUGBANK Trestolone
disease VO dose
disease VO titer
disease VO effectiveness
disease MESH critically ill
drug DRUGBANK Medical air
disease MESH premature mortality
disease VO report
drug DRUGBANK Gold
disease MESH reinfection
disease MESH malaria
pathway KEGG Malaria
disease IDO intervention
disease MESH infectious diseases
disease MESH autism spectrum disorder
disease MESH attention deficit hyperactivity disorder
disease MESH causes
disease IDO blood
disease MESH influenza
disease MESH Parkinson’s disease
disease MESH hearing loss

Original Article

(Visited 1 times, 1 visits today)